REFERENCES
- Diaz L A, Sampaio S A, Rivitti E A, Martins C R, Cunha P R, Lombardi C, Almeida F A, Castro R M, Macca M L, Lavrado C, et al. Endemic pemphigus foliaceus (fogo selvagem). I. Clinical features and immunopathology. J Am Acad Dermatol. 1989; 20: 657–669, [PUBMED], [INFOTRIEVE], [CSA]
- Emery D J, Diaz L A, Fairley J A, Lopez A, Taylor A F, Giudice G J. Pemphigus foliaceus and pemphigus vulgaris autoantibodies react with the extracellular domain of desmoglein-1. J Invest Dermatol. 1995; 104: 323–328, [PUBMED], [INFOTRIEVE], [CSA]
- Adams M J, Reichel M B, King I A, Marsden M D, Greenwood M D, Thirlwell H, Arnemann J, Buxton R S, Ali R R. Characterization of the regulatory regions in the human desmoglein genes encoding the pemphigus foliaceous and pemphigus vulgaris antigens. Biochem J. 1998; 329: 165–174, [PUBMED], [INFOTRIEVE], [CSA]
- Ioannides D, Hytiroglou P, Phelps R G, Bystryn J C. Regional variation in the expression of pemphigus foliaceus, pemphigus erythematosus, and pemphigus vulgaris antigens in human skin. J Invest Dermatol. 1991; 96: 159–161, [PUBMED], [INFOTRIEVE], [CSA]
- Ahmed A R, Dahl M V. Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Arch Dermatol. 2003; 139: 1051–1159, [PUBMED], [INFOTRIEVE], [CSA]
- Kishibe M, Kinouchi M, Ishida-Yamamoto A, Koike K, Iizuka H. Pemphigus foliaceus localized to the nose. Clin Exp Dermatol. 2003; 28: 560–562, [PUBMED], [INFOTRIEVE], [CSA]
- Newton J A, McGibbon D H, Monk B, Rowell N R. Pemphigus foliaceus localized to the nose. Br J Dermatol. 1988; 118: 303–305, [PUBMED], [INFOTRIEVE], [CSA]
- Ahmed A R, Sami N. Intravenous immunoglobulin therapy for patients with pemphigus foliaceus unresponsive to conventional therapy. J Am Acad Dermatol. 2002; 46: 42–49, [PUBMED], [INFOTRIEVE], [CSA]
- Ahmed A R. Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol. 2001; 45: 825–835, [PUBMED], [INFOTRIEVE], [CSA]
- Kazatchkine M D, Kaveri S V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 2001; 345: 747–755, [PUBMED], [INFOTRIEVE], [CSA]
- Sami N, Bhol K C, Ahmed A R. Influence of IVIg therapy on autoantibody titers to desmoglein 1 in patients with pemphigus foliaceus. Clin Immunol. 2002; 105: 192–198, [PUBMED], [INFOTRIEVE], [CSA]
- Ahmed A R. Treatment of autoimmune mucocutaneous blistering diseases with intravenous immunoglobulin therapy. Exp Opin Invest Drugs. 2004; 13: 1019–1032, [CSA]
- Shirakata Y, Amagai M, Hanakawa Y, Nishikawa T, Hashimoto K. Lack of mucosal involvement in pemphigus foliaceus may be due to low expression of desmoglein 1. J Invest Dermatol. 1998; 110: 76–78, [PUBMED], [INFOTRIEVE], [CSA]
- Amagai M, Koch P J, Nishikawa T, Stanley J R. Pemphigus vulgaris antigen (desmoglein 3) is localized in the lower epidermis, the site of blister formation in patients. J Invest Dermatol. 1996; 106: 351–355, [PUBMED], [INFOTRIEVE], [CSA]